Skip to main content
Fig. 6 | Molecular Brain

Fig. 6

From: A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir

Fig. 6

Characterization and validation of ChRII activation with light. On the left are representative whole-cell patch clamp recordings (Vhold = −70 mV) from an mCherry-positive neuron in a DIV 16 primary hippocampal culture infected with rAAVs encoding for mCherry and the channelrhodopsin-2 (ChRII) mutant T159C on DIV 8. Recordings were made from the same cell after 10 min sequential application of blockers (Mg2+, 4 mM; NBQX, 5 μM; MK-801, 10 μM), vehicle (DMSO 0.1%) and Elvitegravir (20 μM). One-hundred ms blue (470 ± 20 nm) light pulses (blue bars) evoke downward inward current deflections with prominent inactivation over the 100 ms pulse duration. The raw response amplitude data for all cells (N = 4 or 5) is plotted on the right as paired observations connected by a line and the paired mean difference is plotted as a bootstrap distribution. Mean differences are depicted as dots with the 95% confidence intervals indicated by the vertical error bars. The p values of the two-sided permutation t-tests are: baseline vs Mg/NBQX/MK-801, 0.125; baseline vs DMSO, 0.757; baseline vs Elvitegravir, 0.747

Back to article page
\